QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
NASDAQ:CDMO

Avid Bioservices - CDMO Stock Forecast, Price & News

$15.81
-0.02 (-0.13%)
(As of 02/1/2023 11:27 AM ET)
Add
Compare
Today's Range
$15.52
$16.14
50-Day Range
$12.61
$17.23
52-Week Range
$11.30
$22.83
Volume
94,877 shs
Average Volume
485,170 shs
Market Capitalization
$985.12 million
P/E Ratio
9.36
Dividend Yield
N/A
Price Target
$22.33

Avid Bioservices MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
43.2% Upside
$22.33 Price Target
Short Interest
Bearish
8.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.71mentions of Avid Bioservices in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$396,316 Sold Last Quarter
Proj. Earnings Growth
1,900.00%
From $0.01 to $0.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

86th out of 1,053 stocks

Pharmaceutical Preparations Industry

32nd out of 519 stocks


CDMO stock logo

About Avid Bioservices (NASDAQ:CDMO) Stock

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Stock News Headlines

Avid Bioservices (NASDAQ:CDMO) Shares Down 5.9%
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Avid Bioservices, Inc. (NASDAQ: CDMO)
RBC Capital Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Is Avid Bioservices (CDMO) a Great Buy?
Read How Avid Bioservices Fared In Q4
Avid Bioservices's Earnings Outlook
See More Headlines
Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Company Calendar

Last Earnings
12/06/2022
Today
2/01/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
4/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.33
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+41.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$127.67 million
Pretax Margin
1.39%

Debt

Sales & Book Value

Annual Sales
$119.60 million
Cash Flow
$0.37 per share
Book Value
$2.83 per share

Miscellaneous

Free Float
61,150,000
Market Cap
$985.12 million
Optionable
Optionable
Beta
1.77

Key Executives

  • Nicholas S. Green
    President, Chief Executive Officer & Director
  • Richard A. Richieri
    Chief Operating Officer
  • Daniel Ryan HartDaniel Ryan Hart
    Chief Financial Officer
  • Nick Ferguson
    Executive Director-Information Technology
  • Mark R. ZiebellMark R. Ziebell
    Secretary, Vice President & General Counsel













CDMO Stock - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDMO shares.
View CDMO analyst ratings
or view top-rated stocks.

What is Avid Bioservices' stock price forecast for 2023?

2 Wall Street analysts have issued 1 year price objectives for Avid Bioservices' shares. Their CDMO share price forecasts range from $20.00 to $25.00. On average, they anticipate the company's share price to reach $22.33 in the next twelve months. This suggests a possible upside of 41.3% from the stock's current price.
View analysts price targets for CDMO
or view top-rated stocks among Wall Street analysts.

How have CDMO shares performed in 2023?

Avid Bioservices' stock was trading at $13.77 on January 1st, 2023. Since then, CDMO shares have increased by 14.8% and is now trading at $15.81.
View the best growth stocks for 2023 here
.

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CDMO earnings forecast
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) posted its quarterly earnings data on Tuesday, December, 6th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The biopharmaceutical company earned $34.76 million during the quarter, compared to analyst estimates of $31 million. Avid Bioservices had a net margin of 88.13% and a trailing twelve-month return on equity of 3.29%.

When did Avid Bioservices' stock split?

Avid Bioservices shares reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2023 earnings guidance on Tuesday, December, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145.00 million-$150.00 million, compared to the consensus revenue estimate of $143.81 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a number of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (1.25%), Sargent Investment Group LLC (1.23%), Redwood Investments LLC (1.13%), Peregrine Capital Management LLC (0.64%), Greenwood Capital Associates LLC (0.11%) and Yousif Capital Management LLC (0.06%). Insiders that own company stock include Daniel R Hart, Daniel Ryan Hart, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends
.

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $15.81.

How much money does Avid Bioservices make?

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $985.12 million and generates $119.60 million in revenue each year. The biopharmaceutical company earns $127.67 million in net income (profit) each year or $1.69 on an earnings per share basis.

How many employees does Avid Bioservices have?

The company employs 252 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817.

This page (NASDAQ:CDMO) was last updated on 2/1/2023 by MarketBeat.com Staff